Rentosertib (ISM001-055), a TNIK inhibitor for idiopathic pulmonary fibrosis: first drug with both an AI-discovered target and AI-designed molecule to reach Phase II; preclinical candidate nomination in 18 months (vs. ~4.5-year industry average) after synthesizing only 78 molecules; Phase IIa showed dose-dependent lung-function improvement

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.